anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

216,061-216,120 of 319,975

filter-aware
23
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics (response rates).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
25
The chart uses a grouped bar structure to compare efficacy across patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
27
The slide uses a two-column layout to compare clinical data for two different indications, supported by competitor market data.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
28
The chart illustrates deepening responses over time in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
31
Includes FDA approval precedents in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
32
The diagram illustrates a classic dose-escalation study design.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
33
The slide uses a mix of expert quotes and a comparative table of clinical trials to validate the outpatient therapy thesis.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
34
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
35
Includes scientific diagrams of molecular pathways and efficacy charts.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
36
Slide contains three distinct data visualizations comparing IMX-110 against standard of care or historical benchmarks.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
37
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in turning cold tumors hot.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
38
Includes survival curves, median survival comparison, and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
39
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
40
Includes waterfall chart for best percentage change and line charts for longitudinal tumor size tracking against PD/PR thresholds.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
41
The slide uses a scatter plot to map clinical trial outcomes (mPFS vs. prior lines of therapy) and a table to detail standard-of-care performance across lines of therapy.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
42
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
43
Includes logos for BeiGene and Novartis at the bottom.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
44
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
45
The slide uses a process-flow style layout to connect platform capabilities to specific therapeutic assets.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
46
The slide uses a process-like structure to map the platform pillars to specific product outputs.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
47
Includes technical diagrams of the drug molecule, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
48
Includes two sets of charts: tumor volume line graphs and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
49
The slide uses a combination of mechanism-of-action diagrams and clinical/preclinical data charts to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
50
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
51
The slide is divided into two sections: ImmixBio Clinical Advisory Board and Select Nexcella Scientific Advisory Board Members.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
52
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
53
The slide is organized into two rows, one for each board, featuring headshots, names, titles, and associated company logos.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
54
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
55
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
56
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
57
The slide uses a bar chart to compare two groups of oncology drugs, highlighting a significant revenue disparity.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
58
The slide uses a bar chart comparison to benchmark existing market leaders against placebo outcomes.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
01
Slide 1
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Humble Origins1 hit
02
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Humble Origins1 hit
03
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Humble Origins1 hit
04
The slide uses a grid layout to present six distinct performance categories.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Humble Origins1 hit
05
The slide uses a process-oriented layout to show four strategic pillars leading to a unified outcome.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early Struggles1 hit
06
The slide uses a timeline to show the divestment of non-luxury assets and acquisition of luxury brands, alongside donut charts to illustrate the shift in revenue composition.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early Struggles1 hit
07
The slide uses a mix of brand logos and a bar chart to illustrate portfolio composition and financial scale.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early Struggles1 hit
08
Uses a before-after framework to illustrate strategic evolution.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
09
The slide uses a split-screen layout comparing Kering Eyewear (historical growth chart) and Kering Beauté (timeline of recent developments).Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising SuccessLoop · Before After1 hit
10
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
11
Includes a quote from the CEO and a visual representation of the top leadership hierarchy.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
12
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
13
Waterfall chart shows H1 22 to H1 23 bridge with Comparable, Scope, and FX impacts. Donut chart includes a central map graphic.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
14
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
15
The slide uses a donut chart to show the 77%/23% split between Retail and Wholesale, with further regional and sub-channel breakdowns.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
16
The slide highlights investment activities and financial health indicators.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
17
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
18
Waterfall chart illustrates revenue bridge between H1 22 and H1 23.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
19
Includes commentary on EBIT margin dilution and CAPEX phasing.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
20
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
21
Waterfall chart shows revenue bridge from H1 22 to H1 23.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
22
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
23
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
24
The chart uses a waterfall bridge to explain revenue variance between H1 2022 and H1 2023.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit